Proteomic detection of nitroproteins as potential biomarkers for cardiovascular disease

Journal of Proteomics

Volumn 74, Issue 11, 2011, Pages 2274-2288

  Aslan, Mutay ^a   Dogan, Serdar ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Biomarker; Cardiovascular disease; Nitroprotein

Indexed keywords

3 NITROTYROSINE; ACTIN; ALBUMIN; ALPHA SYNUCLEIN; ANGIOTENSIN II; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; CREATINE KINASE; CYCLOOXYGENASE 1; CYTOCHROME C; FIBRINOGEN; HISTONE; NITROPROTEIN; PROSTACYCLIN SYNTHASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SUPEROXIDE DISMUTASE; TYROSINE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE MARKER; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NITRATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEOMICS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NITRATES; NITROSATION; NITROSO COMPOUNDS; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEINS; PROTEOMICS;

EID: 80054868098     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.05.029     Document Type: Review

References (121)

1. World Health Organization The world health report 2005.
2. Hochholzer W., Morrow D.A., Giugliano R.P. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J 2010, 160:583-594.
3. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Biomarkers Definitions Working Group. Clin Pharmacol Ther 2001, 69(3):89-95. Mar.
5. Olson S., Robinson S., Giffin R. Accelerating the development of biomarkers for drug safety: workshop summary. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation 2009, 12. Washington (DC): National Academies Press (US.
6. FDA Guidance for industry: pharmacogenomic data submissions 2005, 4. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf.
7. Zhang X., Li L., Wei D., Yap Y., Chen F. Moving cancer diagnostics from bench to bedside. Trends Biotechnol 2007, 25:166-173.
8. Lesko L.J., Atkinson A.J. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001, 41:347-366.
9. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
10. Zhang H., Liu A.Y., Loriaux P., et al. Mass spectrometric detection of tissue proteins in plasma. Mol Cell Proteomics 2007, 6:64-71.
11. Arthur J.M. Proteomics. Curr Opin Nephrol Hypertens 2003, 12:423-430.
12. Arab S., Gramolini A.O., Ping P., et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006, 48:1733-1741.
13. Schopfer F.J., Baker P.R., Freeman B.A. NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response?. Trends Biochem Sci 2003, 28:646-654.
14. Radi R., Cosgrove T.P., Beckman J.S., Freeman B.A. Peroxynitrite-induced luminol chemiluminescence. Biochem J 1993, 290:51-57.
15. Denicola A., Freeman B.A., Trujillo M., Radi R. Peroxynitrite reaction with carbon dioxide/bicarbonate: kinetics and influence on peroxynitrite-mediated oxidations. Arch Biochem Biophys 1996, 333:49-58.
16. Van der Vliet A., Eiserich J.P., Halliwell B., Cross C.E. Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 1997, 272:7617-7625.
17. Brennan M.L., Wu W., Fu X., et al. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem 2002, 277:17415-17427.
18. Baldus S., Eiserich J.P., Brennan M.L., Jackson R.M., Alexander C.B., Freeman B.A. Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of myeloperoxidase as a catalyst for tyrosine nitration in inflammatory diseases. Free Radic Biol Med 2002, 33:1010.
19. Tsikas D., Caidahl K. Recent methodological advances in the mass spectrometric analysis of free and protein-associated 3-nitrotyrosine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 814:1-9.
20. Abello N., Kerstjens H.A., Postma D.S., Bischoff R. Protein tyrosine nitration: selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. J Proteome Res 2009, 8:3222-3238.
21. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005, 563:23-60.
22. Zhan X., Desiderio D.M. The human pituitary nitroproteome: detection of nitrotyrosyl-proteins with two-dimensional Western blotting, and amino acid sequence determination with mass spectrometry. Biochem Biophys Res Commun 2004, 325:1180-1186.
23. Aslan M., Ryan T.M., Townes T.M., Coward L., Kirk M.C., Barnes S., Alexander C.B., Rosenfeld S.S., Freeman B.A. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem 2003, 278:4194-4204.
24. Zheng L., Settle M., Brubaker G., et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005, 280:38-47.
25. Tambor V., Fucíková A., Lenco J., et al. Application of proteomics in biomarker discovery: a primer for the clinician. Physiol Res 2010, 59:471-497.
26. Kislinger T., Emili A. Going global: protein expression profiling using shotgun mass spectrometry. Curr Opin Mol Ther 2003, 5:285-293.
27. Willard B.B., Ruse C.I., Keightley J.A., Bond M., Kinter M. Site-specific quantitation of protein nitration using liquid chromatography/tandem mass spectrometry. Anal Chem 2003, 75:2370-2376.
28. Horvatovich P.L., Bischoff R. Current technological challenges in biomarker discovery and validation. Eur J Mass Spectrom (Chichester, Eng) 2010, 16:101-121.
29. Hüttenhain R., Malmström J., Picotti P., Aebersold R. Perspectives of targeted mass spectrometry for protein biomarker verification. Curr Opin Chem Biol 2009, 13:518-525.
30. Kuzyk M.A., Smith D., Yang J., et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009, 8:1860-1877.
31. Danielson S.R., Held J.M., Schilling B., Oo M., Gibson B.W., Andersen J.K. Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal Chem 2009, 81:7823-7828.
32. Ventura-Clapier R., Kaasik A., Veksler V. Structural and functional adaptations of striated muscles to CK deficiency. Mol Cell Biochem 2004, 256-257:29-41.
33. Wyss M., Smeitink J., Wevers R.A., Wallimann T. Mitochondrial creatine kinase: a key enzyme of aerobic energy metabolism. Biochim Biophys Acta 1992, 1102:119-166.
34. Ventura-Clapier R., Veksler V., Hoerter J.A. Myofibrillar creatine kinase and cardiac contraction. Mol Cell Biochem 1994, 133-134:125-144.
35. Ingwall J.S., Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004, 95:135-145.
36. Tian R., Ingwall J. Energetic basis for reduced contractile reserve in isolated rat hearts. Am J Physiol 1996, 270:1207-1216.
37. Hamman B.L., Bittl J.A., Jacobus W.E., et al. Inhibition of the creatine kinase reaction decreases the contractile reserve of isolated rat hearts. Am J Physiol 1995, 269:1030-1036.
38. Ingwall J.S., Kramer M.F., Fifer M.A., et al. The creatine kinase system in normal and diseased human myocardium. N Engl J Med 1985, 313:1050-1054.
39. Nascimben L., Ingwall J.S., Pauletto P., et al. Creatine kinase system in failing and nonfailing human myocardium. Circulation 1996, 94:1894-1901.
40. Nakae I., Mitsunami K., Omura T., et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol 2003, 42:1587-1593.
41. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190-2196.
42. Mihm M.J., Coyle C.M., Schanbacher B.L., Weinstein D.M., Bauer J.A. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 2001, 49:798-807.
43. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., VanWagoner D.R. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104:174-180.
44. Periasamy M., Kalyanasundaram A. SERCA pump isoforms: their role in calcium transport and disease. Muscle Nerve 2007, 35:430-442.
45. 2+ pumps. Ann N Y Acad Sci 1992, 671:1-10.
46. 2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology. Cardiovasc Res 2008, 77:265-273.
47. Knyushko T.V., Sharov V.S., Williams T.D., Schöneich C., Bigelow D.J. 3-Nitrotyrosine modification of SERCA2a in the aging heart: a distinct signature of the cellular redox environment. Biochemistry 2005, 44:13071-13081.
48. 2+-ATPase in skeletal muscle. Biochem J 1999, 340:657-669.
49. Bigelow D.J. Nitrotyrosine-modified SERCA2: a cellular sensor of reactive nitrogen species. Pflugers Arch 2009, 457:701-710.
50. 2+ transport. Circ Res 2003, 93:487-490.
51. 2+-ATPase in human heart failure. Circulation 2005, 111:988-995.
52. Khaitlina S.Y. Functional specificity of actin isoforms. Int Rev Cytol 2001, 202:35-98.
53. Kabsch W., Vandekerckhove Structure and function of actin. J Annu Rev Biophys Biomol Struct 1992, 21:49-76.
54. Sheterline P., Clayton J., Sparrow J. Actin. Protein Profile 1995, 2:1-103.
55. Holmes K.C., Popp D., Gebhard W., Kabsch W. Atomic model of the actin filament. Nature 1990, 347:44-49.
56. Otterbein L.R., Graceffa P., Dominguez R. The crystal structure of uncomplexed actin in the ADP state. Science 2001, 293:708-711.
57. Kabsch W., Mannherz H.G., Suck D., Pai E.F., Holmes K.C. Atomic structure of the actin:DNase I complex. Nature 1990, 347:37-44.
58. Snook J.H., Li J., Helmke B.P., Guilford W.H. Peroxynitrite inhibits myofibrillar protein function in an in vitro assay of motility. Free Radic Biol Med 2008, 44:14-23.
59. Cai L., Wang Y., Zhou G., et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 48:1688-1697.
60. Cines D.B., Pollak E.S., Buck C.A., et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
61. Gertler J.P., Abbott W.M. Prothrombotic and fibrinolytic function of normal and perturbed endothelium. J Surg Res 1992, 52:89-95.
62. Bombeli T., Mueller M., Haeberli A. Anticoagulant properties of the vascular endothelium. Thromb Haemost. 1997, 77:408-423.
63. Pechik I., Madrazo J., Mosesson M.W., Hernandez I., Gilliland G.L., Medved L. Crystal structure of the complex between thrombin and the central "E" region of fibrin. Proc Natl Acad Sci USA 2004, 101:2718-2723.
64. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984, 311:501-505.
65. Yang Z., Mochalkin I., Veerapandian L., Riley M., Doolittle R.F. Crystal structure of native chicken fibrinogen at 5.5-A resolution. Proc Natl Acad Sci USA 2000, 97:3907-3912.
66. Murthy S.N., Wilson J.H., Lukas T.J., Veklich Y., Weisel J.W., Lorand L. Transglutaminase-catalyzed crosslinking of the Aalpha and gamma constituent chains in fibrinogen. Proc Natl Acad Sci USA 2000, 97:44-48.
67. Vadseth C., Souza J.M., Thomson L., et al. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 2004, 279:8820-8826.
68. Heffron S.P., Parastatidis I., Cuchel M., et al. Inflammation induces fibrinogen nitration in experimental human endotoxemia. Free Radic Biol Med 2009, 47:1140-1146.
69. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
70. Malkowski M.G., Ginell S.L., Smith W.L., Garavito R.M. The productive conformation of arachidonic acid bound to prostaglandin synthase. Science 2000, 289:1933-1937.
71. Picot D., Loll P.J., Garavito R.M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994, 367:243-249.
72. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
73. Mayes P.A. Metabolism of unsaturated fatty acids and eicosanoids. Harper's biochemistry 1996, 236-244. Stanford: Appleton Lange, CT. R.K. Murray, D.K. Granner, P.A. Mayes, V.W. Rodwell (Eds.).
74. Marnett L.J., Rowlinson S.W., Goodwin D.C., Kalgutkar A.S., Lanzo C.A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem 1999, 274:22903-22906.
75. Shimokawa T., Kulmacz R.J., DeWitt D.L., Smith W.L. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J Biol Chem 1990, 265:20073-20076.
76. Thuresson E.D., Lakkides K.M., Smith W.L. Different catalytically competent arrangements of arachidonic acid within the cyclooxygenase active site of prostaglandin endoperoxide H synthase-1 lead to the formation of different oxygenated products. J Biol Chem 2000, 275:8501-8507.
77. Dietz R., Nastainczyk W., Ruf H.H. Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2. Eur J Biochem 1988, 171:321-328.
78. Salvemini D., Seibert K., Masferrer J.L., Misko T.P., Currie M.G., Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994, 93:1940-1947.
79. Salvemini D., Currie M.G., Mollace V. Nitric oxide-mediated cyclooxygenase activation. A key event in the antiplatelet effects of nitrovasodilators. J Clin Invest 1996, 97:2562-2568.
80. Motta A.B., Gonzalez E.T., Rudolph I., Gimeno M.F. Regulation of prostaglandin production by nitric oxide in rat smooth muscle myometrial cells. Prostaglandins Leukot Essent Fatty Acids 1999, 60:73-76.
81. Landino L.M., Crews B.C., Timmons M.D., Morrow J.D., Marnett L.J. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 1996, 93:15069-15074.
82. Trostchansky A., O'Donnell V.B., Goodwin D.C., et al. Interactions between nitric oxide and peroxynitrite during prostaglandin endoperoxide H synthase-1 catalysis: a free radical mechanism of inactivation. Free Radic Biol Med 2007, 42:1029-1038.
83. Deeb R.S., Shen H., Gamss C., et al. Inducible nitric oxide synthase mediates prostaglandin h2 synthase nitration and suppresses eicosanoid production. Am J Pathol 2006, 168:349-362.
84. Deeb R.S., Resnick M.J., Mittar D., McCaffrey T., Hajjar D.P., Upmacis R.K. Tyrosine nitration in prostaglandin H(2) synthase. J Lipid Res 2002, 43:1718-1726.
85. Helliwell R.J., Adams L.F., Mitchell M.D. Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids 2004, 70:101-113.
86. Schmidt P., Youhnovski N., Daiber A., et al. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 2003, 278:12813-12819.
87. Zou M.H., Leist M., Ullrich V. Selective nitration of prostacyclin synthase and defective vasorelaxation in atherosclerotic bovine coronary arteries. Am J Pathol 1999, 154:1359-1365.
88. Zou M.H., Shi C., Cohen R.A. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 2002, 5:198-203.
89. Frank P.G., Marcel Y.L. Apolipoprotein A-I: structure-function relationships. J Lipid Res 2000, 41:853-872.
90. Borhani D.W., Rogers D.P., Engler J.A., Brouillette C.G. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation. Proc Natl Acad Sci USA 1997, 94:12291-12296.
91. Jonas A., Wald J.H., Toohill K.L., Krul E.S., Kézdy K.E. Apolipoprotein A-I structure and lipid properties in homogeneous, reconstituted spherical and discoidal high density lipoproteins. J Biol Chem 1990, 265:22123-22129.
92. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
93. Von Eckardstein A., Nofer J.R., Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001, 21:13-27.
94. Brooks-Wilson A., Marcil M., Clee S.M., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999, 22:336-345.
95. Bodzioch M., Orsó E., Klucken J., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999, 22:347-351.
96. Rust S., Rosier M., Funke H., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999, 22:352-355.
97. Croop J.M. Evolutionary relationships among ABC transporters. Methods Enzymol 1998, 292:101-116.
98. Wang N., Wu X.S., Li C., Feng M.F. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: I. Synthesis and characterization. J Biomater Sci Polym Ed 2000, 11:301-318.
99. Schaefer E.J., Zech L.A., Schwartz D.E., Brewer H.B. Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 1980, 93:261-266.
100. Horowitz B.S., Goldberg I.J., Merab J., Vanni T.M., Ramakrishnan R., Ginsberg H.N. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 1993, 91:1743-1752.
101. Gillotte K.L., Zaiou M., Lund-Katz S., et al. Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem 1999, 274:2021-2028.
102. Panagotopulos S.E., Witting S.R., Horace E.M., Hui D.Y., Maiorano J.N., Davidson W.S. The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1. J Biol Chem 2002, 277:39477-39484.
103. Palgunachari M.N., Mishra V.K., Lund-Katz S., et al. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol 1996, 16:328-338.
104. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta 1991, 1084:205-220.
105. Fielding C.J., Shore V.G., Fielding P.E. A protein cofactor of lecithin:cholesterol acyltransferase. Biochem Biophys Res Commun 1972, 46:1493-1498.
106. Dhoest A., Zhao Z., De Geest B., et al. Role of the Arg123-Tyr166 paired helix of apolipoprotein A-I in lecithin:cholesterol acyltransferase activation. J Biol Chem 1997, 272:15967-15972.
107. Frank P.G., N'Guyen D., Franklin V., et al. Importance of central alpha-helices of human apolipoprotein A-I in the maturation of high-density lipoproteins. Biochemistry 1998, 37:13902-13909.
108. Shao B., Bergt C., Fu X., et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem 2005, 280:5983-5993.
109. Zheng L., Nukuna B., Brennan M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004, 114:529-541.
110. Zweier J.L., Fertmann J., Wei G. Nitric oxide and peroxynitrite in postischemic myocardium. Antioxid Redox Signal 2001, 3:11-22.
111. Parastatidis I., Thomson L., Fries D.M., et al. Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice. Circ Res 2007, 101:368-376.
112. Shishehbor M.H., Aviles R.J., Brennan M.L., et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289:1675-1680.
113. Prassl R., Laggner P. Molecular structure of low density lipoprotein: current status and future challenges. Eur Biophys J 2009, 38:145-158.
114. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
115. Chen S.H., Yang C.Y., Chen P.F., et al. The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 1986, 261:12918-12921.
116. Yang C.Y., Chen S.H., Gianturco S.H., et al. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature 1986, 323:738-742.
117. Segrest J.P., Jones M.K., De Loof H., Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001, 42:1346-1367.
118. Asatryan L., Hamilton R.T., Isas J.M., Hwang J., Kayed R., Sevanian A. LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J Lipid Res 2005, 46:115-122.
119. Graham A., Hogg N., Kalyanaraman B., O'Leary V., Darley-Usmar V., Moncada S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 1993, 330:181-185.
120. Hamilton R.T., Asatryan L., Nilsen J.T., et al. LDL protein nitration: implication for LDL protein unfolding. Arch Biochem Biophys 2008, 479:1-14.
121. Leeuwenburgh C., Hardy M.M., Hazen S.L., et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997, 272:1433-1436.